22 Jul Gordian Biotechnology
Francisco LePort, Ph.D., Co-founder and CEO
Oct. 9 | 11:45am | FLW Ballroom G
San Francisco, CA
(Private)
Gordian has scaled in vivo discovery of gene therapies, bringing gene therapy to complex disease. We inject a pooled library of hundreds of gene therapies, each targeting a different gene or combination, into an individual animal model of disease, turning the target tissue into a mosaic. Using single cell sequencing as phenotypic readout, we separately measure the in vivo efficacy of each gene therapy simultaneously for the indication. We have screened over 1000 gene therapies across three indications to date: Heart Failure, Metabolic Associated Steatohepatitis (MASH), and Osteoarthritis, building the largest in vivo gene perturbation dataset on the planet. Top hits have been validated in preclinical gene therapy POC experiments and will advance toward IND enabling studies and clinical development both internally and through pharma partnerships. For these collaborations, we solve target risk where a partner wants to leverage established gene therapy delivery technology for a complex indication.
